Patients taking Dilantin should be aware of ______ as a common side effect.

A. "Report reddish-brown urine to the provider immediately.": Phenazopyridine commonly causes reddish-orange urine because of its dye component. This effect is harmless and expected, so reporting it as an emergency is unnecessary. Teaching focuses on reassuring the patient about this normal discoloration.

B. "The drug provides symptomatic relief of pain.": Phenazopyridine is a urinary analgesic that helps reduce dysuria, burning, and urinary discomfort. It does not treat the infection itself but offers comfort while antibiotics work, making this the correct teaching point.

C. "Do not take this drug concurrently with an antibiotic.": Phenazopyridine is safely used along with antibiotics to relieve symptoms until the infection is controlled. Avoiding concurrent use would delay comfort without clinical benefit.

D. "This drug has antiseptic and analgesic properties.": Phenazopyridine does not have antiseptic or antimicrobial action. It does not eliminate bacteria and plays no role in infection control, only symptom relief.

A. "I will use this as needed for acute symptoms.": Montelukast is not a rescue medication and should not be used for acute asthma attacks. It is a leukotriene receptor antagonist intended for daily maintenance therapy to prevent bronchoconstriction. Using it for sudden symptoms could delay appropriate treatment.

B. "I will need to have periodic laboratory tests while taking this medication.": Routine lab monitoring is generally not required for montelukast, as it does not significantly affect kidney, liver, or blood parameters in most patients. Ordering unnecessary labs indicates a misunderstanding of the medication’s safety profile.

C. “I will take one tablet daily at bedtime.": This statement demonstrates correct understanding, as montelukast is taken once daily, typically in the evening, to provide optimal control of nocturnal symptoms.

D. "I will begin participating in a smoking cessation program at work.": Engaging in smoking cessation is appropriate and beneficial for respiratory health, complementing asthma management and montelukast therapy.